SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001140361-22-020324
Filing Date
2022-05-24
Accepted
2022-05-23 20:55:33
Documents
2
Group Members
INNOVIVA MERGER SUB, INC.INNOVIVA STRATEGIC OPPORTUNITIES LLC

Document Format Files

Seq Description Document Type Size
1 SC 13D/A ny20004305x2_sc13da.htm SC 13D/A 94814
2 EXHIBIT 99.1 ny20004305x2_ex99-1.htm EX-99.1 7530
  Complete submission text file 0001140361-22-020324.txt   104288
Mailing Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010
Business Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010 6502389600
Innoviva, Inc. (Filed by) CIK: 0001080014 (see all company filings)

IRS No.: 943265960 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 2834 Pharmaceutical Preparations

Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Subject) CIK: 0001724344 (see all company filings)

IRS No.: 824592913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90651 | Film No.: 22953636
SIC: 2834 Pharmaceutical Preparations